Role of the P2X7 receptor in breast cancer progression

被引:2
作者
Du, Yanan [1 ]
Cao, Yahui [1 ]
Song, Wei [1 ]
Wang, Xin [1 ]
Yu, Qingqing [1 ]
Peng, Xiaoxiang [1 ]
Zhao, Ronglan [1 ]
机构
[1] Shandong Second Med Univ, Sch Med Lab, Weifang 261053, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; Tumor progression; SIGNALING PATHWAY; CELL INVASIVENESS; P2X(7) RECEPTOR; IN-VITRO; ACTIVATION; MIGRATION; EXPRESSION; TARGET; ATP; DIFFERENTIATION;
D O I
10.1007/s11302-024-10039-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Breast cancer is a common malignant tumor, whose incidence is increasing year by year, and it has become the malignant tumor with the highest incidence rate in women. Purine ligand-gated ion channel 7 receptor (P2X7R) is a cation channel receptor with Adenosine triphosphate ( ATP) as a ligand, which is widely distributed in cells and tissues, and is closely related to tumorigenesis and progression. P2X7R plays an important role in cancer by interacting with ATP. Studies have shown that P2X7R is up-regulated in breast cancer and can promote tumor invasion and metastasis by activating the protein kinase B (AKT) signaling pathway, promoting epithelial-mesenchymal transition (EMT), controlling the generation of extracellular vesicle (EV), and regulating the expression of the inflammatory protein cyclooxygenase 2 (COX-2). Furthermore, P2X7R was proven to play an essential role in the proliferation and apoptosis of breast cancer cells. Recently, inhibitors targeting P2X7R have been found to inhibit the progression of breast cancer. Natural P2X7R antagonists, such as rhodopsin, and the isoquinoline alkaloid berberine, have also been shown to be effective in inhibiting breast cancer progression. In this article, we review the research progress of P2X7R and breast cancer intending to provide new targets and directions for breast cancer treatment.
引用
收藏
页数:9
相关论文
共 91 条
[1]   International union of pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy [J].
Abbracchio, Maria P. ;
Burnstock, Geoffrey ;
Boeynaems, Jean-Marie ;
Barnard, Eric A. ;
Boyer, Jose L. ;
Kennedy, Charles ;
Knight, Gillian E. ;
Fumagalli, Marta ;
Gachet, Christian ;
Jacobson, Kenneth A. ;
Weisman, Gary A. .
PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :281-341
[2]   The P2X7 receptor: A main player in inflammation [J].
Adinolfi, Elena ;
Giuliani, Anna Lisa ;
De Marchi, Elena ;
Pegoraro, Anna ;
Orioli, Elisa ;
Di Virgilio, Francesco .
BIOCHEMICAL PHARMACOLOGY, 2018, 151 :234-244
[3]   Purine and purinergic receptors in health and disease [J].
Ai, Yanling ;
Wang, Hengyi ;
Liu, Lu ;
Qi, Yulin ;
Tang, Shiyun ;
Tang, Jianyuan ;
Chen, Nianzhi .
MEDCOMM, 2023, 4 (05)
[4]   A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases [J].
Arulkumaran, Nishkantha ;
Unwin, Robert J. ;
Tam, Frederick W. K. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (07) :897-915
[5]   Activation of P2X7 and P2Y11 purinergic receptors inhibits migration and normalizes tumor-derived endothelial cells via cAMP signaling [J].
Avanzato, D. ;
Genova, T. ;
Pla, A. Fiorio ;
Bernardini, M. ;
Bianco, S. ;
Bussolati, B. ;
Mancardi, D. ;
Giraudo, E. ;
Maione, F. ;
Cassoni, P. ;
Castellano, I. ;
Munaron, L. .
SCIENTIFIC REPORTS, 2016, 6
[6]   Mapping the Site of Action of Human P2X7 Receptor Antagonists AZ11645373, Brilliant Blue G, KN-62, Calmidazolium, and ZINC58368839 to the Intersubunit Allosteric Pocket [J].
Bin Dayel, Anfal ;
Evans, Richard J. ;
Schmid, Ralf .
MOLECULAR PHARMACOLOGY, 2019, 96 (03) :355-363
[7]   P2X7 Receptor Promotes Mouse Mammary Cancer Cell Invasiveness and Tumour Progression, and Is a Target for Anticancer Treatment [J].
Brisson, Lucie ;
Chadet, Stephanie ;
Lopez-Charcas, Osbaldo ;
Jelassi, Bilel ;
Ternant, David ;
Chamouton, Julie ;
Lerondel, Stephanie ;
Le Pape, Alain ;
Couillin, Isabelle ;
Gombault, Aurelie ;
Trovero, Fabrice ;
Chevalier, Stephan ;
Besson, Pierre ;
Jiang, Lin-Hua ;
Roger, Sebastien .
CANCERS, 2020, 12 (09) :1-23
[8]   Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer [J].
Bui, Quyen Thu ;
Im, Ji Hye ;
Jeong, Sung Baek ;
Kim, Young-Mi ;
Lim, Sung Chul ;
Kim, Bumseok ;
Kang, Keon Wook .
CANCER LETTERS, 2017, 390 :115-125
[9]   The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression [J].
Burnstock, Geoffrey ;
Knight, Gillian E. .
PURINERGIC SIGNALLING, 2018, 14 (01) :1-18
[10]   The role of P2X7 receptor in infection and metabolism: Based on inflammation and immunity [J].
Cai, Xiaoyu ;
Yao, Yao ;
Teng, Fei ;
Li, Yangling ;
Wu, Linwen ;
Yan, Wei ;
Lin, Nengming .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 101